Seyedehsan Navabi

Seyedehsan Navabi

Auto-generated profile, based on publicly available information

Seyedehsan Navabi

United Medical Doctors, Gastroenterology , Murrieta, CA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
ATAndrew Tinsley
Andrew Tinsley
SNSeyedehsan Navabi
Seyedehsan Navabi
EWEmmanuelle D Williams
Emmanuelle D Williams
GLGuodong Liu
Guodong Liu
LKLan Kong
Lan Kong
KCKofi Clarke
Kofi Clarke
Diseases of immune dysregulation are associated with an increased risk of viral infections, some of which may be preventable. To date, there are very limited data on the incidence and risk of influenza and related complications in patients with inflammatory bowel disease (IBD). Furthermore, the impact of immunosuppressive medications on that risk is unclear. Therefore, the aim of this study was to estimate the incidence and severity of influenza infections in IBD patients. In addition, we looked specifically at the effect of medications on influenza risk. Using the MarketScan Database (January 2008 to December 2011), we conducted a retrospective cohort study to estimate the incidence of influenza and risk of related complications in IBD patients compared with those without IBD. We employed a nested case–control study design to evaluate the potential independent effect of IBD medications on influenza risk. A total of 140,480 patients with IBD and non-IBD controls were studied. There were 2963 patients with influenza compared with 1941 non-IBD subjects. Inflammatory bowel disease patients had an increased influenza risk compared with those without IBD (incidence rate ratio, 1.58; 95% confidence interval [CI], 1.49–1.68). A higher rate of hospitalizations (162/2994 [5.4%] vs 36/1941 [1.85%]; P < 0.001) was noted. Systemic corticosteroids were found to be independently associated with influenza (odds ratio, 1.22; 95% CI, 1.08–1.38). Inflammatory bowel disease patients had an increased risk of influenza compared with those without IBD and were more likely to require hospitalization. Steroids were the only medication class independently associated with flu risk.

1 June 2020 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
JSJonathan G Stine
Jonathan G Stine
ISIan Schreibman
Ian Schreibman
SNSeyedehsan Navabi
Seyedehsan Navabi
MKMitchell Kang
Mitchell Kang
JDJessica Dahmus
Jessica Dahmus
CSChristopher Sciamanna
Christopher Sciamanna
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide affecting upwards of one third the global population. For reasons not fully understood, individuals with NAFLD and its more severe variant, nonalcoholic steatohepatitis (NASH), are at increased risk for venous thromboembolism which significantly increases morbidity and mortality. Lifestyle changes centering around exercise training are the mainstay of treatment for NAFLD/NASH. While exercise training can lessen venous thromboembolic risk in healthy persons and those with cardiovascular disease, whether or not this benefit is seen in patients with NAFLD/NASH remains unknown. In order to better understand how exercise training impacts thrombosis risk in NAFLD, we present the design of a thirty-two week randomized controlled clinical trial of 42 sedentary subjects age 18-69 with biopsy proven NASH. The main aim is to determine the impact of an aerobic exercise training program on the abnormal hemostatic system unique to NAFLD/NASH. The main outcome is change in plasminogen activator inhibitor one level, an established marker for venous thromboembolism. Secondary outcomes include body composition, cardiorespiratory fitness, control of comorbid metabolic conditions (e.g., obesity, hypertension, hyperlipidemia, diabetes), dietary composition, health related quality of life, liver enzymes and histology, NAFLD/NASH disease activity (e.g., biomarkers, clinical decision aids), microbiome, other markers of hemostasis, and PNPLA3 gene expression. The study represents the first clinical trial of an exercise training program to reduce elevated clotting risk in subjects with NAFLD/NASH.

1 May 2018 in Gastroenterology
Verified
Journal Article
Closed access
MCMatthew Coates
Matthew Coates
CSChristopher Soriano
Christopher Soriano
SNSeyedehsan Navabi
Seyedehsan Navabi
VGVenkata Subhash Gorrepati
Venkata Subhash Gorrepati
AJAnsh Johri
Ansh Johri
EWEmmanuelle D. Williams
Emmanuelle D. Williams

16 June 2026 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
ALAlejandro Chen Liang
Alejandro Chen Liang
YCYeison Cruz Castillo
Yeison Cruz Castillo
LBLorena M. Murrieta Bruciaga
Lorena M. Murrieta Bruciaga
OMOlivia Murga
Olivia Murga
APArti A. Patel
Arti A. Patel
EMErnesto Calderon Martinez
Ernesto Calderon Martinez

9 May 2026 in United European Gastroenterology Journal
Verified
Journal Article
Open access
AHAilsa Hart
Ailsa Hart
SNSeyedehsan Navabi
Seyedehsan Navabi
GDGeert D'HAens
Geert D'HAens
KMKatsuyoshi Matsuoka
Katsuyoshi Matsuoka
MMMARIA DOLORES MARTIN-ARRANZ
MARIA DOLORES MARTIN-ARRANZ
SDSilvio Danese
Silvio Danese
Background: Mirikizumab demonstrated efficacy in moderately‐to‐severely active ulcerative colitis, including in patients with prior advanced therapy failure (PATF) (Phase 3: LUCENT‐1 [NCT03518086], LUCENT‐2 [NCT03524092]). This post hoc analysis evaluates mirikizumab efficacy by number/mechanism of PATF. Methods: LUCENT‐1 patients received 300 mg mirikizumab or placebo; mirikizumab induction responders entered LUCENT‐2 and received 200 mg mirikizumab or placebo until week (W)52. Mirikizumab induction non‐responders received extended induction with open‐label 300 mg mirikizumab between W12 and W24. Extended induction responders received open‐label 200 mg mirikizumab between W24 and W52. In each population, efficacy was analyzed by subgroups based on PATF number (0, 1, ≥ 2 [2–3]) and mechanism (including difficult‐to‐treat [DTT]: anti‐TNF plus tofacitinib and/or vedolizumab). Results: At baseline, 479/1162 patients (41.2%) had (≥ 1) PATF, of which 177 (37.0%) had DTT. Among mirikizumab‐treated patients ( n = 868), W12 clinical response was achieved by 69.8%, 63.9%, 45.3%, and 41.9% of the 0‐PATF, 1‐PATF, ≥ 2‐PATF, and DTT subgroups, respectively. 42.1% (365/868) continued with maintenance treatment. Among W12 responders, 51.9% (0‐PATF), 44.2% (1‐PATF), 49.0% (≥ 2‐PATF), and 42.9% (DTT) achieved clinical remission at W52. Over half of the patients (54.0% [147/272]) in the extended induction population had PATF; 51.0% (75/147) were DTT. At W24, clinical response was achieved by 62.4%, 41.4%, 49.5%, and 49.3% of the 0‐PATF, 1‐PATF, ≥ 2‐PATF, and DTT subgroups. Of this 49.3% of the DTT subgroup (extended induction responders), 38.9% (14/36) achieved W52 clinical remission. Conclusions: Mirikizumab induction and maintenance is efficacious in moderately‐to‐severely active ulcerative colitis with or without prior failure of advanced therapy, including difficult‐to‐treat disease. Trail Registration: LUCENT‐1: NCT03518086; LUCENT‐2: NCT03524092

24 September 2026 in Crohn's & Colitis 360
Verified
Journal Article
Open access
MLMillie Long
Millie Long
DLDavid Laharie
David Laharie
GRGerhard Rogler
Gerhard Rogler
SNSeyedehsan Navabi
Seyedehsan Navabi
AVAisha Vadhariya
Aisha Vadhariya
Alessandro ArmuzziAlessandro Armuzzi
Alessandro Armuzzi
Background: Mirikizumab, an anti-interleukin-23p19 monoclonal antibody approved for ulcerative colitis (UC) and Crohn’s disease, was evaluated in LUCENT-URGE (NCT05767021), a phase 3b, open-label study assessing its effect on bowel urgency (BU) through week (W)28 in adults with moderately-to-severely active UC, using novel BU measures and validated quality of life (QoL) instruments. Methods: Patients with UC experiencing BU (baseline severity ≥3 on the urgency numeric rating scale [UNRS]) received 300 mg mirikizumab intravenously at W0, W4, and W8, then 200 mg subcutaneously at W12 and every 4 weeks up to W24. Improvements in QoL and patient-reported outcomes were assessed from baseline to W12 and W28. Results: Among 172 patients, 58.1% achieved clinically meaningful improvement (≥3-point reduction in UNRS), and 37.8% reached BU remission (rounded UNRS ≤ 1) by W28. Inflammatory Bowel Disease Questionnaire (IBDQ) scores improved by 56.4 points, with 52.3% of patients achieving IBDQ-remission (IBDQ ≥ 170) and 65.7% achieving IBDQ-response (≥16-point increase) at W28. Absorbent product use for BU dropped from 55.1% at baseline to 29.6% at W28. Patients reporting no sexual activity avoidance (SAA) due to UC symptoms rose from 21.1% to 51.4%. Activity impairment, Wexner Incontinence Score, and anxiety symptoms also showed improvements. Conclusion: The majority of mirikizumab-treated patients achieved clinically meaningful BU improvement over 28 weeks. In addition to QoL improvement, patients experienced reduced disruption of daily activities, with meaningful reductions in SAA and use of protective aids due to BU. Achieving BU remission or clinically meaningful improvement with mirikizumab was associated with improvements in patients’ relevant UC symptoms and overall QoL.